<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Keratosis pilaris</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Keratosis pilaris</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Keratosis pilaris</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Megan N Landis, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12170590"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Keratosis pilaris (KP) is a common disorder of follicular keratinization characterized by keratotic follicular papules with variable perifollicular erythema. Lesions involve predominantly the extensor aspects of proximal arms, thighs, and cheeks  (<a class="graphic graphic_picture graphicRef90711 graphicRef60786 graphicRef68488" href="/d/graphic/90711.html" rel="external">picture 1A-C</a>). KP is often seen in association with atopic dermatitis and ichthyosis vulgaris [<a href="#rid1">1</a>].</p><p>This topic will review KP. Keratosis pilaris atrophicans and other follicular keratotic syndromes are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91429.html" rel="external">"Keratosis pilaris atrophicans"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15680.html" rel="external">"Lichen planopilaris"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15283.html" rel="external">"Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p></p><p class="headingAnchor" id="H12170596"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Onset of KP typically occurs in children or adolescents without sex predilection. It is seen in all ethnic groups, with an estimated prevalence of 2 to 12 percent in pediatric populations [<a href="#rid2">2-4</a>].</p><p class="headingAnchor" id="H12170602"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The cause of KP is not fully understood but has been associated with filaggrin mutations [<a href="#rid5">5,6</a>]. It is thought to be a genetic disorder of keratinization that results in the formation of horny plugs in the hair follicle orifices. The mode of inheritance has not been determined, although in many cases it fits into an autosomal dominant pattern with incomplete penetrance. Patients with a generalized form of KP have been found to have a chromosome 18p deletion [<a href="#rid7">7,8</a>]. There are a few reports of KP induced by <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">nilotinib</a>, a second-generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myeloid leukemia [<a href="#rid9">9-12</a>].</p><p class="headingAnchor" id="H7211695"><span class="h1">PATHOLOGY</span><span class="headingEndMark"> — </span>An orthokeratotic keratin plug, which may contain one or more twisted hairs, fills and dilates the infundibulum of the hair follicle and protrudes above the skin surface  (<a class="graphic graphic_picture graphicRef90745" href="/d/graphic/90745.html" rel="external">picture 2</a>). There may be a mild perivascular lymphocytic infiltrate in the upper dermis [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H12170608"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>KP typically manifests during childhood or adolescence but may also occur in infants  (<a class="graphic graphic_picture graphicRef122242" href="/d/graphic/122242.html" rel="external">picture 3</a>) [<a href="#rid14">14</a>]. It presents with spiny keratotic papules predominantly involving the extensor aspects of proximal arms and thighs. The face, trunk, buttocks, and distal extremities may also be affected  (<a class="graphic graphic_picture graphicRef122241 graphicRef90711 graphicRef60786 graphicRef68488" href="/d/graphic/122241.html" rel="external">picture 1A-D</a>). The papules may be grouped or scattered, and there is often an associated mild perifollicular erythema.</p><p>KP is usually asymptomatic and may be an incidental finding during physical examination. Some patients report a rough texture and an unsightly appearance of their skin. Since KP is associated with other skin conditions, such as atopic dermatitis or ichthyosis vulgaris, these conditions may also be seen on the patient's skin.</p><p>Exacerbation during the winter months is common, likely due to xerosis or friction from thick clothing [<a href="#rid15">15</a>]. Worsening during pregnancy has also been reported  (<a class="graphic graphic_picture graphicRef90712" href="/d/graphic/90712.html" rel="external">picture 4</a>) [<a href="#rid16">16</a>]. KP usually improves with age but may persist into adult life [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H20798811"><span class="h2">Clinical variants</span><span class="headingEndMark"> — </span>In some patients, perifollicular erythema may be prominent, particularly on the cheeks, forehead, and neck  (<a class="graphic graphic_picture graphicRef77270" href="/d/graphic/77270.html" rel="external">picture 5A</a>). This form of KP is called "keratosis pilaris rubra" [<a href="#rid17">17</a>].</p><p>"Erythromelanosis follicularis faciei et colli" is another variant of KP, primarily seen in adolescents and young adults. It presents with erythema, hyperpigmentation, and follicular papules involving the temples and cheeks with extension to the preauricular areas and sides of the neck  (<a class="graphic graphic_picture graphicRef90772" href="/d/graphic/90772.html" rel="external">picture 5B</a>) [<a href="#rid18">18,19</a>]. Follicular keratotic papules, similar to simple KP, are often found on the extensor aspects of the arms.</p><p class="headingAnchor" id="H20798938"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>KP is commonly seen in patients with ichthyosis vulgaris and atopic dermatitis [<a href="#rid20">20</a>]. It is also reported in association with type 1 diabetes mellitus [<a href="#rid21">21</a>] and obesity [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/15471.html" rel="external">"Ichthyosis vulgaris"</a>.)</p><p class="headingAnchor" id="H12170620"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of KP is clinical, based upon the finding of spiny keratotic papules with variable erythema involving the extensor aspects of proximal arms and thighs  (<a class="graphic graphic_picture graphicRef90711 graphicRef60786 graphicRef68488" href="/d/graphic/90711.html" rel="external">picture 1A-C</a>). Involvement of the eyebrows, marked inflammation, and atrophic scarring with alopecia suggest the diagnosis of KP atrophicans.</p><p>Biopsy is usually not necessary; if performed, it reveals a dilated follicular infundibulum and an orthokeratotic keratin plug. (See <a class="local">'Pathology'</a> above.)</p><p class="headingAnchor" id="H1308200630"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of KP includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen spinulosus</strong> – Lichen spinulosus is typically only seen in pediatric patients and is characterized by small, follicular papules with keratotic spines that coalesce into larger patches distributed symmetrically on the trunk and extremities  (<a class="graphic graphic_picture graphicRef87590" href="/d/graphic/87590.html" rel="external">picture 6</a>). Lichen spinulosus typically spontaneously remits [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phrynoderma</strong> – Phrynoderma is characterized by follicular hyperkeratosis, with papules first appearing on the extensor surfaces on the extremities, shoulders, and buttocks  (<a class="graphic graphic_picture graphicRef90760" href="/d/graphic/90760.html" rel="external">picture 7</a>). It is caused by vitamin A deficiency or general malnutrition [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Deficiency'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Keratosis pilaris atrophicans</strong> – Keratosis pilaris atrophicans is a group of rare genodermatoses characterized by follicular keratosis, a variable degree of inflammation and secondary scarring, and/or alopecia [<a href="#rid26">26</a>]. They include keratosis pilaris atrophicans faciei (also called ulerythema ophryogenes), atrophoderma vermiculatum, and keratosis follicularis spinulosa decalvans. The face and in particular the lateral eyebrows and cheeks are typically involved  (<a class="graphic graphic_picture graphicRef90732 graphicRef122244 graphicRef95125" href="/d/graphic/90732.html" rel="external">picture 8A-C</a>) [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/91429.html" rel="external">"Keratosis pilaris atrophicans"</a>.)</p><p></p><p>Follicular keratosis is also seen in Darier disease  (<a class="graphic graphic_picture graphicRef70000 graphicRef56168" href="/d/graphic/70000.html" rel="external">picture 9A-B</a>) and perforating dermatoses  (<a class="graphic graphic_picture graphicRef86830" href="/d/graphic/86830.html" rel="external">picture 10</a>) disease. However, their clinical presentation is remarkably different from KP [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/15462.html" rel="external">"Darier disease"</a>.)</p><p class="headingAnchor" id="H12170632"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>KP may improve with age without treatment; however, it very commonly waxes and wanes throughout one's lifetime into early and middle adulthood. It is, however, less commonly seen in older patients. However, patients with widespread KP and/or intense erythema who have cosmetic concerns may request treatment to reduce skin roughness and erythema. Improvement is usually temporary; responsive patients should be educated to maintain therapy to achieve continued remission.</p><p>All patients with KP may benefit from skin care measures aimed at preventing excessive skin dryness, including using mild soaps or soap-free cleansers and avoiding hot baths or showers [<a href="#rid28">28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Emollients and keratolytics</strong> – Emollients and topical keratolytics are the first-line therapy for KP. Preparations containing lactic acid, salicylic acid, or topical <a class="drug drug_general" data-topicid="10031" href="/d/drug information/10031.html" rel="external">urea</a> are helpful in softening and flattening the keratotic papules, but do not reduce or relieve the associated erythema [<a href="#rid29">29</a>]. In a series of 30 patients with widespread KP, a preparation of salicylic acid 2% in topical urea cream 20% applied to the involved skin for several weeks was effective in improving the skin texture and appearance [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical retinoids</strong> – Topical retinoids (eg, tretinoin 0.05% cream, <a class="drug drug_general" data-topicid="9352" href="/d/drug information/9352.html" rel="external">adapalene</a> 0.1% cream, or <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a> 0.05% cream) may be used as a second-line therapy for patients who fail to respond to emollients and keratolytics. Topical retinoids are applied once a day for 8 to 12 weeks. In a small, randomized trial, tazarotene 0.05% cream was more effective than placebo in reducing itching, roughness, and redness in patients with more than 20 hyperkeratotic papules on the posterior upper arms [<a href="#rid31">31</a>]. In a small, open study, tazarotene 0.01% emulsion reduced or resolved KP lesions in four to eight weeks [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroids</strong> – Short courses of low- to medium-potency topical corticosteroids (groups 4 to 6  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>)) may be used in conjunction with other topical agents if there is prominent inflammation [<a href="#rid30">30</a>]. Topical corticosteroids are applied to the involved areas once or twice daily for one to two weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other therapies</strong> – Third-line therapies include systemic retinoids, laser therapy [<a href="#rid33">33</a>], or other ablative procedures. Combination treatments with lasers (eg, pulsed dye laser, long-pulsed 755 nm alexandrite laser, 810 nm long-pulsed diode laser, long-pulsed 1064 nm neodymium-doped yttrium aluminum garnet [Nd:YAG] laser) and microdermabrasion have been tried in a few patients with temporary reduction of perifollicular erythema and skin roughness [<a href="#rid34">34-37</a>]. (See  <a class="medical medical_review" href="/d/html/37.html" rel="external">"Light-based, adjunctive, and other therapies for acne vulgaris", section on 'Microdermabrasion'</a>.)</p><p></p><p class="headingAnchor" id="H20799500"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Keratosis pilaris (KP) is a common disorder of follicular keratinization. It typically appears during childhood or adolescence with spiny, keratotic papules  (<a class="graphic graphic_picture graphicRef68488" href="/d/graphic/68488.html" rel="external">picture 1C</a>) predominantly involving the extensor aspects of proximal arms and thighs  (<a class="graphic graphic_picture graphicRef90711" href="/d/graphic/90711.html" rel="external">picture 1A</a>). The face, trunk, buttocks, and distal extremities may also be affected. Variants with prominent background erythema have been described  (<a class="graphic graphic_picture graphicRef77270 graphicRef90772" href="/d/graphic/77270.html" rel="external">picture 5A-B</a>). KP is often seen in association with atopic dermatitis and ichthyosis vulgaris. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Clinical variants'</a> above and <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of KP is clinical, based on clinical features. Involvement of the eyebrows, marked inflammation, and atrophic scarring with alopecia suggest the diagnosis of keratosis pilaris atrophicans  (<a class="graphic graphic_picture graphicRef90732 graphicRef122244 graphicRef95125" href="/d/graphic/90732.html" rel="external">picture 8A-C</a>). (See <a class="local">'Diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/d/html/91429.html" rel="external">"Keratosis pilaris atrophicans"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – KP typically improves with age without treatment. However, for patients with widespread KP who have cosmetic concerns, treatment with emollients and topical keratolytics can provide symptomatic relief. Topical retinoids (eg, tretinoin 0.05% cream, <a class="drug drug_general" data-topicid="9352" href="/d/drug information/9352.html" rel="external">adapalene</a> 0.1% cream, or <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a> 0.05% cream) are a second-line therapy for patients who fail to respond to emollients and keratolytics. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H2794935009"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jennifer Perryman, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hwang S, Schwartz RA. Keratosis pilaris: a common follicular hyperkeratosis. Cutis 2008; 82:177.</a></li><li><a class="nounderline abstract_t">Del Pozzo-Magaña BR, Lazo-Langner A, Gutiérrez-Castrellón P, Ruiz-Maldonado R. Common Dermatoses in Children Referred to a Specialized Pediatric Dermatology Service in Mexico: A Comparative Study between Two Decades. ISRN Dermatol 2012; 2012:351603.</a></li><li><a class="nounderline abstract_t">Popescu R, Popescu CM, Williams HC, Forsea D. The prevalence of skin conditions in Romanian school children. Br J Dermatol 1999; 140:891.</a></li><li><a class="nounderline abstract_t">Inanir I, Sahin MT, Gündüz K, et al. Prevalence of skin conditions in primary school children in Turkey: differences based on socioeconomic factors. Pediatr Dermatol 2002; 19:307.</a></li><li><a class="nounderline abstract_t">Gruber R, Sugarman JL, Crumrine D, et al. Sebaceous gland, hair shaft, and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency. Am J Pathol 2015; 185:1012.</a></li><li><a class="nounderline abstract_t">Landeck L, Visser M, Kezic S, John SM. Genotype-phenotype associations in filaggrin loss-of-function mutation carriers. Contact Dermatitis 2013; 68:149.</a></li><li><a class="nounderline abstract_t">Nazarenko SA, Ostroverkhova NV, Vasiljeva EO, et al. Keratosis pilaris and ulerythema ophryogenes associated with an 18p deletion caused by a Y/18 translocation. Am J Med Genet 1999; 85:179.</a></li><li><a class="nounderline abstract_t">Zouboulis CC, Stratakis CA, Gollnick HP, Orfanos CE. Keratosis pilaris/ulerythema ophryogenes and 18p deletion: is it possible that the LAMA1 gene is involved? J Med Genet 2001; 38:127.</a></li><li><a class="nounderline abstract_t">Leong WM, Aw CW. Nilotinib-Induced Keratosis Pilaris. Case Rep Dermatol 2016; 8:91.</a></li><li><a class="nounderline abstract_t">Shimizu A, Hattori M, Takeuchi Y, Ishikawa O. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib. J Dermatol 2016; 43:1100.</a></li><li><a class="nounderline abstract_t">Tawil MH, El Khoury R, Tomb R, Ghosn M. Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning. Int J Trichology 2017; 9:87.</a></li><li><a class="nounderline abstract_t">Kowe PA, Wankhade VH, Malpani SS, Singh RP. Nilotinib-induced generalized keratosis pilaris: Report of a rare case. Indian J Pharmacol 2021; 53:330.</a></li><li class="breakAll">Weedon D. Weedon's Skin Pathology, 3rd ed, Churchill Livingstone, 2010.</li><li><a class="nounderline abstract_t">Castela E, Chiaverini C, Boralevi F, et al. Papular, profuse, and precocious keratosis pilaris. Pediatr Dermatol 2012; 29:285.</a></li><li><a class="nounderline abstract_t">Poskitt L, Wilkinson JD. Natural history of keratosis pilaris. Br J Dermatol 1994; 130:711.</a></li><li><a class="nounderline abstract_t">Jackson JB, Touma SC, Norton AB. Keratosis pilaris in pregnancy: an unrecognized dematosis of pregnancy? W V Med J 2004; 100:26.</a></li><li><a class="nounderline abstract_t">Marqueling AL, Gilliam AE, Prendiville J, et al. Keratosis pilaris rubra: a common but underrecognized condition. Arch Dermatol 2006; 142:1611.</a></li><li><a class="nounderline abstract_t">Sardana K, Relhan V, Garg V, Khurana N. An observational analysis of erythromelanosis follicularis faciei et colli. Clin Exp Dermatol 2008; 33:333.</a></li><li><a class="nounderline abstract_t">Augustine M, Jayaseelan E. Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris. Indian J Dermatol Venereol Leprol 2008; 74:47.</a></li><li><a class="nounderline abstract_t">Mevorah B, Marazzi A, Frenk E. The prevalence of accentuated palmoplantar markings and keratosis pilaris in atopic dermatitis, autosomal dominant ichthyosis and control dermatological patients. Br J Dermatol 1985; 112:679.</a></li><li><a class="nounderline abstract_t">Pavlović MD, Milenković T, Dinić M, et al. The prevalence of cutaneous manifestations in young patients with type 1 diabetes. Diabetes Care 2007; 30:1964.</a></li><li><a class="nounderline abstract_t">Boza JC, Trindade EN, Peruzzo J, et al. Skin manifestations of obesity: a comparative study. J Eur Acad Dermatol Venereol 2012; 26:1220.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol 2007; 56:901.</a></li><li><a class="nounderline abstract_t">Friedman SJ. Lichen spinulosus. Clinicopathologic review of thirty-five cases. J Am Acad Dermatol 1990; 22:261.</a></li><li><a class="nounderline abstract_t">Maronn M, Allen DM, Esterly NB. Phrynoderma: a manifestation of vitamin A deficiency?... The rest of the story. Pediatr Dermatol 2005; 22:60.</a></li><li class="breakAll">Paller AS, Mancini AJ. Disorders of hair and nails. In: Hurwitz Clinical Pediatric Dermatology, 4th ed, Elsevier Saunders, 2011.</li><li><a class="nounderline abstract_t">Arnold AW, Buechner SA. [Keratosis pilaris and keratosis pilaris atrophicans faciei]. J Dtsch Dermatol Ges 2006; 4:319.</a></li><li><a class="nounderline abstract_t">Garwood JD. Keratosis pilaris. Am Fam Physician 1978; 17:151.</a></li><li class="breakAll">James WD, Berger T, Elston D. Andrews' Diseases of the Skin: Clinical Dermatology, 11th ed, Saunders, 2011.</li><li><a class="nounderline abstract_t">Novick NL. Practical management of widespread, atypical keratosis pilaris. J Am Acad Dermatol 1984; 11:305.</a></li><li><a class="nounderline abstract_t">Bogle MA. Tazarotene 0.05% cream for the treatment of keratosis pilaris. J Am Acad Dermatol 2004; 50:P39.</a></li><li><a class="nounderline abstract_t">Gerbig AW. Treating keratosis pilaris. J Am Acad Dermatol 2002; 47:457.</a></li><li><a class="nounderline abstract_t">Kechichian E, Jabbour S, El Hachem L, et al. Light and Laser Treatments for Keratosis Pilaris: A Systematic Review. Dermatol Surg 2020; 46:1397.</a></li><li><a class="nounderline abstract_t">Lee SJ, Chung WS, Kim J, Cho SB. Combination of 595-nm pulsed dye laser, long-pulsed 755-nm alexandrite laser and microdermabrasion treatment for keratosis pilaris. J Dermatol 2012; 39:479.</a></li><li><a class="nounderline abstract_t">Lee SJ, Choi MJ, Zheng Z, et al. Combination of 595-nm pulsed dye laser, long-pulsed 755-nm alexandrite laser, and microdermabrasion treatment for keratosis pilaris: retrospective analysis of 26 Korean patients. J Cosmet Laser Ther 2013; 15:150.</a></li><li><a class="nounderline abstract_t">Saelim P, Pongprutthipan M, Pootongkam S, et al. Long-pulsed 1064-nm Nd:YAG laser significantly improves keratosis pilaris: a randomized, evaluator-blind study. J Dermatolog Treat 2013; 24:318.</a></li><li><a class="nounderline abstract_t">Ibrahim O, Khan M, Bolotin D, et al. Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial. JAMA Dermatol 2015; 151:187.</a></li></ol></div><div id="topicVersionRevision">Topic 13663 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18856156" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Keratosis pilaris: a common follicular hyperkeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097714" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Common Dermatoses in Children Referred to a Specialized Pediatric Dermatology Service in Mexico: A Comparative Study between Two Decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354028" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The prevalence of skin conditions in Romanian school children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12220273" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of skin conditions in primary school children in Turkey: differences based on socioeconomic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660180" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Sebaceous gland, hair shaft, and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23421459" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genotype-phenotype associations in filaggrin loss-of-function mutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406673" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Keratosis pilaris and ulerythema ophryogenes associated with an 18p deletion caused by a Y/18 translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11288714" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Keratosis pilaris/ulerythema ophryogenes and 18p deletion: is it possible that the LAMA1 gene is involved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27194977" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nilotinib-Induced Keratosis Pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028020" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28839396" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34414913" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nilotinib-induced generalized keratosis pilaris: Report of a rare case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34414913" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nilotinib-induced generalized keratosis pilaris: Report of a rare case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22141376" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Papular, profuse, and precocious keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011494" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Natural history of keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15119494" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Keratosis pilaris in pregnancy: an unrecognized dematosis of pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17178988" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Keratosis pilaris rubra: a common but underrecognized condition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201261" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : An observational analysis of erythromelanosis follicularis faciei et colli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187825" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Erythromelanosis follicularis faciei et colli: relationship with keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4005167" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The prevalence of accentuated palmoplantar markings and keratosis pilaris in atopic dermatitis, autosomal dominant ichthyosis and control dermatological patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519431" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The prevalence of cutaneous manifestations in young patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21929550" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Skin manifestations of obesity: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17504714" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Obesity and the skin: skin physiology and skin manifestations of obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2179296" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Lichen spinulosus. Clinicopathologic review of thirty-five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660900" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phrynoderma: a manifestation of vitamin A deficiency?... The rest of the story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660900" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phrynoderma: a manifestation of vitamin A deficiency?... The rest of the story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638061" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Keratosis pilaris and keratosis pilaris atrophicans faciei].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/622941" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/622941" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6480934" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Practical management of widespread, atypical keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Tazarotene 0.05% cream for the treatment of keratosis pilaris</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196765" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Treating keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32804891" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Light and Laser Treatments for Keratosis Pilaris: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21973291" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Combination of 595-nm pulsed dye laser, long-pulsed 755-nm alexandrite laser and microdermabrasion treatment for keratosis pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23464682" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Combination of 595-nm pulsed dye laser, long-pulsed 755-nm alexandrite laser, and microdermabrasion treatment for keratosis pilaris: retrospective analysis of 26 Korean patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268726" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-pulsed 1064-nm Nd:YAG laser significantly improves keratosis pilaris: a randomized, evaluator-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372313" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
